公开(公告)号：US20220273586A1

公开(公告)日：2022-09-01

申请号：US17637581

申请日：2020-08-26

申请人： KENT STATE UNIVERSITY

发明人： Min-Ho KIM ,  Songping D. HUANG ,  Ronghui SONG ,  Bing YU

IPC分类号： A61K31/122 ,  A61K31/431 ,  A61K31/5383 ,  A61K31/496 ,  A61K38/14 ,  C07C45/74 ,  A61P31/04

摘要： Naphthoquinone derivatives of Lawsone have been found to be effective against Staphylococcus aureus and methicillin resistant Staphylococcus aureus (MRSA). Such compounds generally contain a substituent group at the 3-position of a specific naphthoquinone compound, i.e. 2-hydroxy-1,4-naphthoquinone. One of these derivatives referred to as compound 6c in the series exhibits potent antimicrobial activity that is comparable to that of the two commercial antibiotics ofloxacin and ciprofloxacin against the two strains of methicillin sensitive Staphylococcus aureus (MSSA; ATCC 29213 and ATCC 6538). In the case of two strains of MRSA (ATCC BAA-44 and ATCC BAA-1717) that have developed drug resistance to both ofloxacin and ciprofloxacin, the antimicrobial activity of 6c can almost rival that of vancomycin and daptomycin. Furthermore, 6c is also effective against vancomycin-intermediate and daptomycin non-susceptible strain of MRSA (ATCC 700699). Besides the efficacy, 6c has a much improved drug resistance profile in comparison with the conventional antibiotics.

公开(公告)号：US20160220500A1

公开(公告)日：2016-08-04

申请号：US14941081

申请日：2015-11-13

申请人： KENT STATE UNIVERSITY

发明人： Songping D. HUANG ,  Gail C. FRAIZER ,  Vindya S. PERERA

IPC分类号： A61K9/51 ,  A61K33/32 ,  A61K33/26 ,  C01G39/06 ,  C01G45/00 ,  C01G49/12 ,  C01G41/00 ,  A61K33/24 ,  C01B17/42

CPC分类号： A61K9/51 ,  A61K9/19 ,  A61K9/5138 ,  A61K31/28 ,  A61K33/24 ,  A61K33/26 ,  A61K33/32 ,  A61P35/00 ,  C01B17/42 ,  C01G39/06 ,  C01G41/006 ,  C01G45/006 ,  C01G49/12

摘要： This invention describes a new type of covalent-network ternary inorganic metal sulfide compounds M1M2S4 (M1, independently, is, Mg, Ca, Mn, Fe, or Zn; M2=Mo or W) and a process for preparing the biocompatible nanoparticles of such compounds. The nanoparticles are surface-modified with a capping agent and/or a biocompatible polymer and have the size from a few nanometers to several thousand nanometers. These nanoparticles are nontoxic and can be internalized by cells to deplete copper ions via a highly selective ion-exchange reaction between the intracellular copper ions and the divalent ion bound in the nanoparticles for the application of inhibiting angiogenesis in cancer and other diseases.

摘要翻译： 本发明描述了一种新型的共价网络三元无机金属硫化物M1M2S4（M1，独立地，Mg，Ca，Mn，Fe或Zn; M2 = Mo或W）以及这样的生物相容纳米颗粒的制备方法 化合物。 纳米颗粒用封端剂和/或生物相容性聚合物进行表面改性并具有几纳米到几千纳米的尺寸。 这些纳米颗粒是无毒的，并且可以被细胞内化以通过细胞内铜离子与纳米颗粒中结合的二价离子之间的高选择性离子交换反应来消耗铜离子，以在癌症和其他疾病中应用抑制血管发生。

公开(公告)号：US20230233477A1

公开(公告)日：2023-07-27

申请号：US18102272

申请日：2023-01-27

申请人： KENT STATE UNIVERSITY

发明人： Songping D. HUANG ,  Min-Ho Kim ,  Bishnu D. PANT ,  Bogdan M. Benin ,  K.G. Nalin Krishantha ABEYdeera

IPC分类号： A61K9/51 ,  A61K33/245

CPC分类号： A61K9/5192 ,  A61K33/245 ,  A61K9/5146 ,  A61K9/5138

摘要： α-Bi2O3 NPs exhibit not only potent broad-spectrum antibacterial activity of killing both Gram-negative (MIC=0.75 μg/mL vs. P. aeruginosa) and Gram-positive (MIC=2.5 μg/mL vs. S. aureus) bacteria, but they are also effective against Ag-resistant and carbapenem-resistant bacteria (MICs=1.0 μg/mL and 1.25 μg/mL, respectively), and they are able to sensitize bacteria towards meropenem (mero), acting synergistically and thus allowing for its continued use with smaller therapeutic doses (fractional inhibitory concentration=0.45). Importantly, unlike other technologies that have been considered as effective metal antimicrobials, α-Bi2O3 NPs do not contribute to the generation of antimicrobial resistant phenotypes with no resistance observed after 30 passages. The Bi-based materials represent a critical tool against multidrug resistant bacteria.

公开(公告)号：US20220409576A1

公开(公告)日：2022-12-29

申请号：US17765262

申请日：2020-11-18

申请人： KENT STATE UNIVERSITY

发明人： Min-Ho KIM ,  Songping D. HUANG ,  Bing YU

IPC分类号： A61K31/366 ,  A61K9/16 ,  A61K31/365 ,  A61P31/04

摘要： Novel biocompatible Fenton-catalytic nano-particulate composites preferably based on nanoparticle (NP)-based catalysts, one or more reducing agents, and one or more peroxide compounds are formulated to take advantage of their ability to stimulate bactericidal as well as anti-tumor immune response by means of eliciting the generation of reactive oxygen species (ROS) in immune cells, in particular, in macrophages. The therapeutic composition can serve as a treatment for wound infections by, but not limited to, Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, Klebsiella pneumoniae, and Acinetobacter baumannii, as a wound/lesion dressing that provide an anti-bacterial immune environment for the accelerated wound healing. In a similar principle, the therapeutic composition can serve as a treatment for solid tumors by providing an anti-tumor immune environment that inhibits tumor growth.